New campaign demonstrates commitment to treating the new millennium epidemic of Atrial Fibrillation
Barcelona, March 19, 2018 – Biosense Webster EMEA, a Division of Johnson & Johnson Medical NV/SA and leader in the treatment of Atrial Fibrillation, is launching its ‘Power to Heal’ campaign across Europe, the Middle East and Africa at the European Heart Rhythm Association (EHRA) Congress 2018. The campaign reflects the company’s ongoing dedication and mission to cure Atrial Fibrillation and alleviate the burden of disease reoccurrence.
Atrial Fibrillation can have life-altering consequences for patients, increasing a patient’s risk of stroke five-fold and mortality two-fold.1 It is fast becoming one of the world’s most significant health issues – affecting 14 million people across Europe, the Middle East and Africa2, as well as placing a critical burden on healthcare systems with up to 2.5% of total healthcare expenditure associated with the disease3.
Despite the significant socio-economic burden associated with the condition, management of Atrial Fibrillation is not optimal. Existing antiarrhythmic drug therapies alone are not well managed for almost half of patients4 and just 4% of eligible patients receive ablation to treat the condition5. Patients often go under-diagnosed and/or are referred too late, when they could instead have access to ablation treatment with success rates reported as high as 92%, as demonstrated with CARTO VISITAG™ Module with Ablation Index6.
“I’m pleased to say that for over 20 years Biosense Webster has pioneered the development of Atrial Fibrillation ablation treatment and through working closely with healthcare professionals have been able to give thousands of patients their lives back” said Gabriele Fischetto, Vice President of Johnson & Johnson Cardiovascular Specialty Solutions in EMEA “but – there are still thousands who are yet to enjoy their lives once again. These patients are our driving force. Through continued partnership and collaboration, we believe that we will be able to power positive outcomes for the benefit of patients, providers and healthcare systems. Together, we have the Power to Heal”.
The Power to Heal campaign, launched at the EHRA Congress, is in direct response to this growing epidemic, where Biosense Webster is hosting a series of educational events designed to help clinicians effectively treat patients with Atrial Fibrillation through radiofrequency ablation.
A satellite symposium entitled ‘Improving the Full Range of AF Ablation Outcomes’ will provide attendees with insight about the value of using contact force technology in treating Atrial Fibrillation, whilst the Agora session ‘How to get better in Paroxismal Atrial Fibrillation Ablation’ will introduce attendees to the latest technologies to reproduce and standardise ablation treatment. In addition, a Learning Village will provide physicians with the opportunity to improve the efficiency of Atrial Fibrillation ablations through practical and presentation-based sessions.
1. Zoni-Berisso M., L. C. D. Epidemiology of atrial fibrillation: European perspective. Clinical Epidemiology 2014:6:213-220
2. Data extracted by Global Burden Disease (GBD) Results Tool - GHDx website 24/10/2017
3. Ball et al. Atrial Fibrillation: Profile and burden of an evolving epidemic in the 21st Century. International Journal of Cardiology 167 (2013) 1807 – 1824.
4. Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y et al. (2009) Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systemic literature review and meta-analyses. Circ Arrhythm Electrophysiol 2 (4): 349 – 361.
5. Pillarisetti J, Lakkireddy D. Atrial fibrillation in Europe: state of the state in disease management! Bloch Heart Rhythm Center, Division of Cardiovascular Diseases, Cardiovascular Research Institute, University of Kansas Hospital & Medical Center, Kansas City, KS. European Heart Journal (2014) 35, 3326–3327
6. Taghji, P. et al. Evaluation of a Strategy Aiming to Enclose the Pulmonary Veins With Contiguous and Optimized Radiofrequency Lesions in Paroxysmal Atrial Fibrillation, Journal of American College of Cardiology: Clinical Electrophysiology, article in press (2017)
© Johnson & Johnson Medical NV/SA 2018 - 087895-180220